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The transcription factor ATF2 elicits oncogenic
activities in melanoma and tumor suppressor activi-
ties in nonmalignant skin cancer. Here, we identify
that ATF2 tumor suppressor function is determined
by its ability to localize at the mitochondria, where
it alters membrane permeability following genotoxic
stress. The ability of ATF2 to reach the mitochondria
is determined by PKCε, which directs ATF2 nuclear
localization. Genotoxic stress attenuates PKCε
effect on ATF2; enables ATF2 nuclear export and
localization at the mitochondria, where it perturbs
the HK1-VDAC1 complex; increases mitochondrial
permeability; and promotes apoptosis. Significantly,
high levels of PKCε, as seen in melanoma cells,
block ATF2 nuclear export and function at the mito-
chondria, thereby attenuating apoptosis following
exposure to genotoxic stress. In melanoma tumor
samples, high PKCε levels associate with poor prog-
nosis. Overall, our findings provide the framework for
understanding how subcellular localization enables
ATF2 oncogenic or tumor suppressor functions.
INTRODUCTION
Activating transcription factor 2 (ATF2) is one of 16 Atf/Creb
family transcription factors and an integral component of the
activator protein-1 (AP-1) transcriptional complex, which regu-
lates normal cellular growth and development, as well as cellular
response to stress (Lopez-Bergami et al., 2010). The diverse
transcriptional functions of ATF2 are attributed to its homo- or
heterodimerization with other AP-1 transcription factors via
a basic leucine zipper (bZIP) domain, in concert with its phos-
phorylation by stress kinases, JNK or p38, on residues 69/71
(Gupta et al., 1995). As a stress-inducible transcription factor,ATF2 regulates gene expression programs implicated in cell-
cycle control, cytokine expression, and cell death (Lopez-
Bergami et al., 2010). In addition to its transcriptional role,
ATF2 functions in the DNA damage response, which requires
ATM-dependent phosphorylation on residues 490/498. Mice
harboring mutations at these sites are more radiosensitive and
genetically unstable when crossed with p53 mutant mice or
when subjected to a skin carcinogenesis protocol (Bhoumik
et al., 2005; Li et al., 2010).
Though the above functions require nuclear localization,
growing evidence points to cytoplasmic localization of ATF2,
although its function there remains elusive. In melanomas,
nuclear ATF2 is associated with metastasis and poor prognosis,
whereas cytoplasmic ATF2 is associated with nonmalignant
skin cancers and better prognosis (Berger et al., 2003). ATF2
transcriptional activity (which requires nuclear localization) is
required for melanoma development, as demonstrated in the
N-Ras/Ink4a mouse melanoma model (Shah et al., 2010). Corre-
spondingly, inhibition of ATF2 nuclear localization by expression
of either 10 or 50 amino acid (aa) peptides derived from ATF2
efficiently attenuates melanoma development (Bhoumik et al.,
2004). In contrast, ATF2 cytosolic localization, as seen in nonma-
lignant skin cancer, is associated with a tumor suppressor role;
inhibiting ATF2 in keratinocytes results in a greater number
of skin papillomas that develop more rapidly than WT ATF2-
expressing keratinocytes (Bhoumik et al., 2008).
We investigated mechanisms underlying the ability of ATF2
to elicit diverse nuclear and cytoplasmic functions and report
that ATF2 functions at themitochondria in response to genotoxic
stress. We found that, at the mitochondrial outer membrane,
ATF2 abrogates formation of high-order complexes containing
hexokinase-1 (HK1) and voltage-dependent anion channel-1
(VDAC1), deregulating mitochondrial outer-membrane perme-
ability and initiating apoptosis. This function is negatively
regulated by PKCε phosphorylation of ATF2, which dictates
its nuclear localization. Of note, elevated expression and
activity of PKCε was reported in different tumor types and is
associated with poorer outcome and inhibition of tumor cellCell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 543
Figure 1. ATF2 Localizes at the Mitochondrial Outer Membrane in Response to Genotoxic Stress
(A) Control, 5 mM etoposide-treated (ETO, overnight treatment), UVC-treated (20 J/m2), ionizing radiation-treated (IR, 5Gy), or 40 ng/ml leptomycin B (LMB) and
ETO cotreated SCC9 cells grown on coverslipswere immunofluorescently stained for HSP60 (red), ATF2 (green), or DNA (blue). Control and ETO panels represent
89% ± 4% and 64% ± 11%, respectively, of the cells from three independent replicate coverslips per condition. n > 100 cells counted per replicate.
(B) Control- or ETO-treated SCC9 cells were harvested for whole-cell lysate (W) or biochemically fractionated to cytoplasmic (C) and mitochondrial (M) fractions
and were subject to immunoblot analysis with indicated antibodies.
(C) Jun2 promoter-luciferase-transfected SCC9 cells were assayed for luciferase activity prior to (Control) or after ETO treatment. *p < 0.0001.
(D) Mitochondria (M) purified from ETO-treated SCC9 cells were subject to proteolysis protection assay with titrated concentrations of trypsin: 0.2 (1), 0.1 (2),
0.05 (3), 0.025 (4), or 0.0125 (5) mg in the absence or presence of 1% Triton X-100 (TX) detergent.
Scale bars, 10 mm. Error bars represent SD. See also Figure S1.death (Bae et al., 2007). Whereas PKCε overexpression pro-
motes the development of squamous carcinomas (Sand
et al., 2010), its inhibition sensitizes tumor cells to cell death
(Gillespie et al., 2005). The identification of mechanisms under-
lying ATF2 subcellular localization and cytosolic function offers
a framework for understanding the regulation of opposing
functions for the same transcription factor.
RESULTS
Genotoxic Stress Induces ATF2 Nuclear Export
and Mitochondrial Localization
Although ATF2 cytoplasmic localization was previously reported
(Berger et al., 2003; Bhoumik et al., 2008; Deng et al., 2008),
a cytoplasmic function has yet to be described. Based on the
observed cytosolic localization of ATF2 in squamous cell
carcinoma (SCC) tumors, we employed a SCC line (SCC9) to
analyze potential ATF2 cytoplasmic function. Mass spectro-
metric (MS) analysis of cytosol-localized ATF2-bound pro-
teins in SCC9 cells identified a cluster of mitochondria-outer
membrane-related proteins, suggesting an ATF2 mitochondrial544 Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc.interaction (Table S1 available online). Indeed, nonstressed
SCC9 cells exhibit predominantly nuclear ATF2, whereas
genotoxic stress rendered by etoposide (ETO) resulted in its
accumulation at mitochondria in 64% of treated cells (Fig-
ure 1A). Other genotoxic insults, including ultraviolet C (UVC,
20 J/m2) and ionizing irradiation (IR, 5Gy), also prompted the
mitochondrial localization of ATF2 (Figure 1A). Themitochondrial
localization of ATF2 following genotoxic stimuli was also seen in
other cell types, including normal human fibroblasts (HSF),
primary human keratinocytes (NHEK), and melanocytes (HEM),
as well as in other SCC cell lines (M7 and P9) (Figure S1). Of
note, whereas some melanoma cell lines (UACC903) exhibit
partial mitochondrial enrichment of ATF2 (Figures S1 and 6D),
a number of melanoma cell lines (LU1205 and 501Mel) (Fig-
ures S1 and 6D) did not exhibit mitochondrial localization of
ATF2 following genotoxic stimuli, with the exception of IR
(Figure S1), suggesting that malignant melanomas are largely
resistant to genotoxic stress-induced mitochondrial transloca-
tion of ATF2. The extent of ATF2 mitochondrial localization
differs among the different cultures and type of stimuli, indicating
variation in cellular response and control of such translocation
in each of these cultures. Biochemical fractionation of SCC9
cells confirmed that exposure to genotoxic stress results in the
accumulation of ATF2 in mitochondrial-enriched fractions
(Figure 1B).
Pretreatment of SCC9 cells with the nuclear export in-
hibitor leptomycin B (LMB) prevented mitochondrial accu-
mulation of ATF2 following ETO treatment, indicating that
nuclear export of ATF2 occurs after genotoxic stress (Figure 1A,
fifth row). Consistently, we observed an 50% reduction of
luciferase activity driven by the ATF2 response element
(Figure 1C).
ATF2 protein does not harbor canonical mitochondrial locali-
zation or peptide-processing signals, which could facilitate
import or insertion into mitochondrial membranes, suggesting
that its mitochondrial localization requires interaction with mito-
chondrial protein(s). Thus, we examined where ATF2 might be
accumulating at the mitochondrial outer membrane (MOM), the
intermembrane space (IMS), the mitochondrial inner membrane
(MIM), or the mitochondrial inner matrix. Limited proteolysis
protection assays with enriched mitochondrial fractions purified
from ETO-treated SCC9 cells revealed efficient degradation of
ATF2 in the absence of detergent, consistent with the degrada-
tion pattern of the MOM component TOM20 but differing from
the pattern of inner-matrix protein COXII, which is degraded
only in the presence of detergent (Figure 1D). These results
suggest that, in response to genotoxic stress, ATF2 localizes
at the MOM.
ATF2 Interacts with HK1:VDAC1 Complexes following
Genotoxic Stress
To determine ATF2 function at mitochondria, we tested MOM
protein(s) identified in our MS analysis (Table S1), hexokinase-1
(HK1) and voltage-dependent anion channel 1 (VDAC1)
(Figure S1), for possible interaction with ATF2.
In response to various forms of stress, HK1 and HK2 bind to
VDAC1, which oligomerizes to form large molecular weight
complexes (Abu-Hamad et al., 2009). To determine whether
ATF2 is part of these complexes, we assessed the distribution
of ATF2, HK1, and VDAC1 in fractions obtained following fast
protein liquid chromatographic (FPLC) analysis using a gel filtra-
tion column. Whereas prior to stress, ATF2 did not codistribute
to fractions with HK1 and VDAC1, after ETO treatment, all three
proteins were found within high molecular weight fractions
(Figure 2A). Of note, not all of the ATF2 protein redistributed to
high MW fractions. The remaining ATF2 in the low MW fraction
is consistent with the residual nuclear ATF2 found by IHC and
the residual (50%) transcriptional activity recorded after ETO
treatment (Figures 1A and 1C, respectively). As shown below,
distinct posttranslational modification of ATF2 is found in these
pools.
To confirm the interaction of ATF2 with HK1 and VDAC1,
we immunoprecipitated endogenous ATF2 or HK1 from cell
lysates of SCC9 cells prior to and after ETO treatment. ATF2
interaction with HK1 and with high molecular weight
(130 kDa) tetrameric VDAC1 oligomers, detectable with the
aid of crosslinker (Zalk et al., 2005), was clearly seen after
ETO treatment (Figure 2B, top and bottom). Interestingly,
knockdown of HK1, but not HK2, abrogated mitochondriallocalization of ATF2 following ETO treatment, indicating that
the mitochondrial localization of ATF2 requires HK1 (Figures
2C, 2D, and S2A).
PKCε Phosphorylation Negatively Regulates ATF2
Mitochondrial Localization
Phosphorylation of ATF2 by p38 or JNK on Thr69/71 is required
for its dimerization with AP-1 transcription factors and for
transcriptional activity (Gupta et al., 1995; van Dam et al.,
1995). However, Thr69/71 phosphorylation was dispensable
for ATF2 mitochondrial localization, as inhibition of either p38
or JNK activity by respective pharmacological inhibitors did
not alter its nuclear localization (Figure S2B).
Analysis of ATF2 protein sequence using the phosphorylation
site scanning program (http://scansite.mit.edu) predicted an
uncharacterized but highly probable PKCε/d/z phosphorylation
site on residue Thr52. Treatment with the PKCε translocation
inhibitor (PKCε-i) promoted mitochondrial localization of ATF2,
even in the absence of ETO, as detected by both IHC and
mitochondrial fractionation (Figures 3A and S3F). Consistently,
siRNA-mediated knockdown of PKCε (Figure S3A) promoted
mitochondrial localization of ATF2 (Figure 3B), whereas overex-
pression of a constitutively active form of PKCε (caPKCε; Pass
et al., 2001) attenuated ATF2 accumulation at mitochondria
following ETO treatment (Figure 3C). As with the genotoxic
stress-induced nuclear export of ATF2 (Figure 1A), LMB
pretreatment blocked its mitochondrial translocation following
PKCε inhibition (Figure S3E). Inhibition of the novel (d) or atypical
(z) PKC forms had negligible effect on mitochondrial ATF2
localization (Figure S3B). These observations indicate that
ATF2 mitochondrial localization is primarily regulated by PKCε.
Of note, Ser729 phosphorylation on PKCε, an indicator of
active PKCε, decreases following overnight treatment with
ETO or with PKCε-i (Figure 3D), suggesting that the effect of
PKCε on the nuclear localization of ATF2 is attenuated following
genotoxic stress, enabling ATF2 nuclear export and mitochon-
drial localization.
To determine whether the predicted ATF2 site (Thr52) for
phosphorylation by PKCε regulates mitochondrial translocation
of ATF2, we assessed PKCε phosphorylation of ATF2 in vitro,
as well as the localization of ATF2T52A (a nonphosphorylatable
alanine phosphomutant) and ATF2T52E (a glutamic acid phos-
phomimic). In vitro kinase assays employing an ATF2 fragment
consisting of aa 50–100 revealed that PKCε phosphorylates the
wild-type (WT), but not the ATF2T52A, peptide. Addition of PKC
catalytic inhibitor Go¨6850 inhibited this phosphorylation (Fig-
ure 3E). Together, these data indicate that Thr52 is a PKCε
phosphoacceptor site. Consistent with the nuclear localization
observed in the presence of caPKCε, the ATF2T52E mutant
exhibited constitutive nuclear localization (Figure 3F), whereas
the ATF2T52A mutant localized to the cytoplasm and mitochon-
dria, even in the absence of genotoxic stress (Figure 3F).
Gel filtration analysis revealed that ATF2T52A, but not ATF2T52E,
distributed to large molecular weight fractions containing
VDAC1 (Figure S3D). Interestingly, expression of ATF2T52A
revealed less HK1 within the high molecular weight VDAC1-
containing fractions, pointing to the possibility that ATF2T52A
may attenuate the interaction between HK1 and VDAC1.Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 545
Figure 2. ATF2 Interacts with VDAC1 and HK1 Complex at the Mitochondria
(A) Control or 5 mM etoposide (ETO, overnight)-treated SCC9 cells were lysed and subject to size exclusion chromatography separation. Every other fraction was
subject to immunoblot analysis with indicated antibodies. Fractions are arranged, left to right, in order of descendingmolecular weight, with control protein weight
markers indicated above (in kDa).
(B) Control- or ETO-treated SCC9 cells were crosslinked and lysed. ATF2 (top) or HK1 (bottom) were immunoprecipitated and subject to immunoblot analysis
with indicated antibodies. Asterisk indicates nonspecific IgG.
(C) Coverslip-grown SCC9 cells knocked down for either HK1 or HK2 and subject to ETO treatment were immunofluorescently stained with indicated antibodies.
(D) Quantitation of mitochondrial ATF2 (MtATF2, gray bars) versus displaced ATF2 (red bars) before or after knockdown of HK1 or HK2. n > 50 cells per replica
in three independent experiments.
Scale bars, 10 mm. Error bars represent SD. See also Figure S2 and Table S1.Collectively, these findings establish that PKCε regulates ATF2
mitochondrial localization via phosphorylation at T52.
Given the effect of PKCε on ATF2 subcellular localization,
we next assessed its effect on ATF2 transcriptional activity.
Overexpression of caPKCε led to a marked increase in Jun2-
luciferase activity, indicative of ATF2 transcriptional activity,
which was largely attenuated upon knockdown of ATF2
(Figure 3G). Interestingly, inhibition with Go¨6850 or ETO treat-
ment reduced Jun2-luciferase activity to similar extents as
knockdown of ATF2, suggesting that PKCε contributes to basal
transcriptional activity of ATF2 in these cells. Consistently,
reconstitution of SCC9 cells carrying a stable knockdown of
ATF2 (employing shRNA targeting ATF2 30UTR) (Figure S3C)
with ATF2T52E also increased Jun2-luciferase activity compared
to ATF2WT. Conversely, mutation of T52 to alanine abolished
ATF2 transcriptional activity (Figure 3H). These findings indicate
that, by regulating ATF2 nuclear localization, PKCε not only
determines ability of ATF2 to reach the mitochondria, but also
its transcriptional activity.546 Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc.Mitochondria-Localized ATF2 Compromises
Outer Membrane Integrity by Disrupting
HK1:VDAC1 Complexes
Disruption of VDAC interaction with HK1 or HK2 sensitizes cells
to stress, promoting MOM leakage of molecules from the IMS
(Abu-Hamad et al., 2009). Conversely, HK1 or HK2 binding to
the MOM promotes resistance to stress and increased cell
survival (Moin et al., 2007; Shoshan-Barmatz et al., 2010; Shulga
et al., 2009). To assess whether interaction with ATF2 perturbs
the HK1/VDAC1 complex, we first evaluated HK1 accumulation
at mitochondria following ectopic expression of the ATF2
phosphomutants that preferentially localize to either the nucleus
(ATF2T52E) or mitochondria (ATF2T52A) (Figures 4 and S4D).
Under basal conditions, HK1 is localized to the cytoplasm
and mitochondria (Figure 4A). Of note, mitochondrial colocaliza-
tion of HK1 was enhanced after ETO treatment (Figure 4B).
In ATF2T52E-transfected cells, HK1 accumulation at mito-
chondria was similar to that seen in control cells prior to and
after ETO treatment (Figures 4G and 4H). However, ATF2T52A
Figure 3. PKCε Phosphorylation of ATF2 on Thr52 Negatively Regulates Its Mitochondrial Localization
(A–C) Coverslip-grown SCC9 cells were immunofluorescently stained with indicated antibodies after: (A) overnight treatment with 1 or 5 mM PKCε translocation
inhibitor (PKCε-i); (B) overnight treatment with 20 nM scrambled control (siSCR) or PKCε-targeted (siPKCε) siRNA; and (C) transfection with HIS-tagged
constitutively active PKCε (caPKCε, red) and treatment with 5 mM etoposide (ETO, overnight).
(D) SCC9 cells treated overnight with ETO or 5 mMPKCε translocation inhibitor (PKCε-i) were lysed and subject to immunoblot analysis with indicated antibodies.
(E) In vitro PKCε kinase assay with Millipore control peptide (CTL), purified GST-ATF2 50–100 aa WT (WT), GST-ATF2 50–100 aa WT + PKCε catalytic inhibitor,
Go¨6850 (WT+Go¨), or GST-ATF2 50–100 aa T52A (T52A) as substrate. *nonspecific bands. Coomassie-stained gel (bottom) and autoradiograph (top) are dis-
played as indicated.
(F) Coverslip-grown SCC9 cells were transfected with HA-tagged wild-type ATF2 (WT), ATF2T52A, or ATF2T52E and were subsequently immunofluorescently
stained with indicated antibodies.
(G) SCC9 control or ATF2 knocked down cells (shATF2) were transfected with Jun2 promoter-luciferase construct, and either empty vector (EV) or caPKCεwere
assayed for luciferase activity before and after overnight ETO or Go¨6850 (2 mM) treatment. ,p = 0.0034; #p = 0.0157.
(H) SCC9 cells stably knocked down for ATF2 with a 30UTR-targeted shRNA were reconstituted with Jun2 promoter-luciferase construct and ATF2WT, ATF2T52A,
or ATF2T52E and were subsequently assayed for luciferase activity. *p = 0.0047.
Scale bars, 10 mm. Error bars represent SD. See also Figure S3.overexpression abrogated mitochondrial accumulation of HK1
prior to and following genotoxic stress, as indicated by
decreased distinct colocalization of HK1 and MitoTracker
(Figures 4E and 4F and insets 4E* and 4F*). Of note, ETO-treated,
ATFT52A-expressing cells exhibited more fragmented mitochon-
dria compared to cells expressing empty vector, ATF2WT, or
ATF2T52E (Figure insets 4E* and 4F*, compared to Figures 4A–
4C, 4G, and 4H). Further, the expression of ATF2T52A promoted
the appearance of punctated, HK1 positively staining structures
that localized near, but not with, the MitoTracker-labeled mito-
chondrial structures (Figures 4E and 4F and insets E* and F*
and Figure S4E). These results indicate that mitochondrial
translocation of ATF2 perturbs HK1/VDAC1 complexes andMOM integrity. ATF2WT also translocated to the mitochondria
and abrogated HK1 localization following genotoxic stress (Fig-
ure 4D). Expression of either ATF2WT or the T52 ATF2 mutants
did not affect VDAC1 multimerization, a change that promotes
mitochondrial leakage and cell death, as assessed by crosslink-
ing and nonreducing immunoblot analysis (data not shown).
Consistent with our IHC data, overexpression of ATF2T52A
abrogated HK1 association with VDAC1 that was immunopre-
cipitated under basal conditions and following genotoxic stress.
Overexpression of ATF2WT abrogated the HK1/VDAC1 complex
only after ETO treatment, whereas the ATF2T52E did not affect
HK1 binding to VDAC1 (Figure 5A). In agreement, HK1 associa-
tion with VDAC1 also decreased following treatment of SCC9Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 547
Figure 4. ATF2T52A Displaces HK1 from Mitochondria
(A–H) Coverslip-grown SCC9 cells were transfected with empty vector (EV) or HA-tagged ATF2 (WT), ATF2T52A, or ATF2T52E in the absence (A, C, E, E*, G) or
presence (B, D, F, F*, H) of 5 mM etoposide (ETO, overnight) and were subsequently immunostained with indicated antibodies and MitoTracker. Yellow
arrowheads indicate HA-positive cells. Scale bars, 10 mm. See also Figure S4.cells with PKCε-i alone or PKCε-i in the presence of ETO (Fig-
ure 5B). These data indicate that mitochondria-localized ATF2
attenuates the ability of HK1 to form a complex with VDAC.
ATF2 Localization at the Mitochondria Reduces
Mitochondrial Potential and Sensitizes Cells to
Genotoxic Stress-Induced Death
We next monitored changes in mitochondrial membrane poten-
tial that are reflective of leakage. We used fluorescence-
activated cell sorting (FACS) to quantify tetramethylrhodamine
ethyl ester (TMRE) uptake, an indicator of relative mitochondrial
membrane potential. Consistent with previous reports (Fu et al.,
2008), low-dose ETO initially increased TMRE uptake by control
SCC9 cells (Figure S4A), whereas increased doses of ETO
reduced TMRE uptake (data not shown).
ATF2T52E-transfected SCC9 cells did not exhibit altered TMRE
uptake compared to empty vector- (EV) or ATF2WT-transfected
cells. These, as well as EV-transfected cells, increased TMRE
uptake following genotoxic stress (Figure S4A). In contrast,548 Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc.ATF2T52A-transfected cells decreased TMRE uptake (Figures
S4A and S4C), consistent with our IHC data, indicating that
mitochondrial ATF2 impairs the formation of HK1/VDAC1
complexes and thus MOM integrity.
As changes in the absolute number of mitochondria (mito-
chondrial mass) need to be monitored in order to determine
net changes in mitochondrial potential, we pulse labeled SCC9
cells with nonyl-acridine orange (NaO) to stain for cardiolipin,
a mitochondrial lipid that is unaffected by altered membrane
potential. ATF2T52A-expressing, but not ATF2T52E-expressing,
cells increased NaO staining, indicating that loss of mitochon-
drial membrane potential increased mitochondrial biogenesis,
likely to compensate for dysfunctional mitochondria (Figures
S4B and S4C), consistent with previous reports (Fu et al.,
2008). Of note, the observed TMRE/NaO ratios, reflective
of membrane potential per mitochondria (mitochondrial
‘‘leakiness’’), indicate that overexpression of ATF2T52A, but not
of ATF2WT or ATF2T52E, decreases membrane potential relative
to control cells (Figures 5C). Correspondingly, only ATF2T52A
Figure 5. ATF2T52A Abrogates HK1:VDAC Association, Promoting Mitochondrial Leakage, Cytochrome C Release, and Cell Death
(A) SCC9 cells were transfected with empty vector (EV) or HA-tagged ATF2 (W), ATF2T52A (A), or ATF2T52E (E) in the presence or absence of 5 mM etoposide
(ETO, overnight), crosslinked and lysed for whole-cell lysate (input), or immunoprecipitated for VDAC1 and subject to immunoblot analysis with indicated
antibodies.
(B) SCC9 cells were treated with ETO (E) or PKCε translocation inhibitor (i, 5 mM) or both (i-E), lysed for whole-cell lysate (input), or immunoprecipitated for
VDAC1 and subject to immunoblot analysis with indicated antibodies.
(C) SCC9 cells transfected with EV, W, A, or E in the presence (red bars) or absence (gray bars) of 5 mM etoposide overnight were pulse labeled with
tetramethylrhodamine ethyl ester (TMRE) or nonyl acridine orange (NaO) and were subsequently analyzed by FACS analysis. Histogram bars represent ratios of
TMRE/NaO uptake. See Figure S4 for individual TMRE and NaO values. n = 10,000 cells per replicate; three replicates per condition were performed. ,p < 0.0001;
#p = 0.01.
(D) Coverslip-grown SCC9 cells transfected with EV, W, A, or E were immunostained for cytochrome c and MitoTracker and analyzed for cytochrome c release
by fluorescence microscopy. n > 100 cells per replicate; three replicates per condition were performed. ,p = 0.0008.
(E) (Right) SCC9 cells treated with PKCε-i (5 mM) alone or in the presence of ETO (overnight) were stained with Annexin-V and propidium iodide (PI) and were
subject to FACS analysis. ,p < 0.0001; #p = 0.6018. Representative FACS plots (left) and corresponding Annexin V-negative and Annexin V-positive (AV, AV+)
percentages are as follows: control (97%, 3%); PKCε-i (92%, 8%); ETO (89.5%, 11.5%); and ETO+PKCε-i (87%, 13%). Averaged value histograms (right) are
displayed as indicated.
(F) SCC9 cells were transfected with EV, W, A, or E in the presence (red bars) or absence (gray bars) of ETO. Cells were stained with Annexin-V and were subject
to FACS analysis. n = 10,000 cells per replicate; three replicates per condition were performed. ,p = 0.0001; #p < 0.0001.
Error bars represent SD. See also Figures S4 and S5.expression induced cytochrome c leakage (Figure 5D, S5D).
Interestingly, the IHC pattern of cytochrome c release is reflec-
tive of partial leakage (Carvalho et al., 2004), suggesting that
mitochondrial ATF2 serves as a priming/initial trigger for sensiti-zation, which precedes cell death. That ATF2WT expression did
not decrease mitochondrial potential or induce cell death (Fig-
ure 5D) could be explained by its susceptibility to be phosphor-
ylated on T52 and retained in the nucleus. Hence, partialCell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 549
Figure 6. PKCε Phosphorylation of ATF2 on Thr52 and Resistance of Melanoma Cells to Genotoxic Stress-Induced Cell Death
(A) SCC9 cells were transfected with empty vector or constitutively active PKCε (caPKCε) and were subject to immunoblot analysis with indicated antibodies.
Densitometric ratios of bands for (caPKCε, +caPKCε) are as follows: pS729/b-actin (0.193, 0.636); pT52/Total ATF2 (0.215, 0.662).
(B) Control or ATF2 knocked down LU1205 cells were subject to immunoblot analysis with indicated antibodies.
(C) Indicated cell lines were subject to etoposide treatment (10 mM, ETO, overnight) and subject to immunoblot analysis with indicated antibodies. Densitometric
band ratios for pT52/Total ATF2 (ETO, +ETO) are as follows: SCC9 (1, 0.4), UACC903 (1, 0.7), 501Mel (1, 0.9), LU1205 (1, 1). Densitometric band ratios for
pS729/Total PKCε (ETO, +ETO) are as follows: SCC9 (1, 0.7), UACC903 (1, 0.7), 501Mel (1, 0.97), LU1205 (1, 1).
(D) Control or ETO-treated coverslip-grown LU1205, 501Mel, or UACC903 cells were immunofluorescently stained with indicated antibodies.
(E) 501Mel cells treatedwith 10 mMPKCε translocation inhibitor (PKCε-i) alone or in the presence or absence of 5 mMetoposide (ETO, overnight) were stained with
Annexin-V and subject to FACS analysis. n = 10,000 cells per replicate; three replicates per condition were performed. ,p = 0.0009; #p = 0.0001.
Error bars represent SD. See also Figure S6.inhibition of PKCε is expected to allow partial nuclear retention
of ATF2, whereas ATF2T52A is largely excluded from the nuclei.
Indeed, nuclear localization is seen in 40% of the ATF2WT-ex-
pressing cells (Figure S4D), which may dampen the effect
elicited by the cytosolic ATF2. These observations suggest
that a minimal level of ATF2 must reach the mitochondria in
order to affect membrane potential and to promote cell death.
As mitochondrial leakage often precedes cell death, we eval-
uated whether mitochondria-localized ATF2 would sensitize
cells to genotoxic stress-induced cell death. We examined
how PKCε inhibition affected SCC9 cells exposed to genotoxic
stress. Cells treated with PKCε-i exhibited increased Annexin-V
labeling, similar to ETO-treated cells (Figure 5E). The latter is
consistent with the observation that PKCε activation was
equally attenuated upon ETO or PKCε-i treatment (Figure 3D).
Furthermore, cells subjected to PKCε-i or siRNA-mediated
knockdown of PKCε also exhibited increased cell death after
ETO or UVC (20 J/m2) treatment (Figures S5A and S5B). Consis-
tently, expression of ATF2T52A, but not ATF2WT or ATF2T52E, also
resulted in elevated cell death, regardless of genotoxic stress
(Figure 5F).
Given the importance of Bax in the permeabilization of
mitochondria and control of cell death, we assessed possible
changes in the conformation and thus activation of Bax.
Using antibodies recognizing active conformation of Bax,550 Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc.we revealed that ATF2T52A promotes active Bax conformation,
whereas ATF2T52E attenuates such conformation (Figure S5E).
PKCε Expression Increases T52 Phosphorylation
of ATF2 and Melanoma Cells’ Resistance
to Genotoxic Stress
Tomonitor PKCε phosphorylation of ATF2 on T52, we generated
a polyclonal antibody against phosphorylated T52 (pT52 anti-
body). caPKCε overexpression in SCC9 cells resulted in the
appearance of a slower-migrating band that was recognized
by total and pT52 ATF2 antibodies (Figure 6A). Both total ATF2
and pT52 ATF2 bands were no longer detectable upon ATF2
knockdown (Figure 6B).
We next evaluated the status of pT52 in SCC9 as well as
melanoma cell lines prior to and after genotoxic stress. Consis-
tent with reduced PKCε phosphorylation of ATF2 on T52, pT52
levels were lower in SCC9 cells subjected to ETO treatment
(Figure 6C). Of note, whereas decreased T52 phosphorylation
was also apparent in ETO-treated UACC903 cells, it was
much less pronounced in 501Mel and LU1205 cells. These find-
ings are consistent with the relationship between PKCε activity
and the ability of ATF2 to translocate to the mitochondria
following genotoxic stress. Respectively, UACC903 cells, but
not LU1205 or 501Mel cells, exhibited partial mitochondrial
translocation of ATF2 following ETO treatment (Figures 6C
Figure 7. PKCε and Phospho-T52 ATF2 Expression in Normal Cells and Malignant Tumors
(A) Primary keratinocytes (NHEK) and melanocytes (HEM), squamous carcinoma (M7, P9, SCC9), and melanoma (501Mel, LU1205, WM793, and UACC903) cell
lines were subject to immunoblot analysis with indicated antibodies. Histogram represents ratio A/B, where A = densitometric ratio values of pT52/total ATF2
bands and B = densitometric ratio values of pS729/total PKCε bands.
(B) Box plots showing distribution of PKCε in metastatic (left) and primary (right) specimens. PKCε levels are denoted on the y axis (p < 0.0001, t statistic –4.257).
The mean ± one standard deviation is depicted by the horizontal bars and is higher in the metastatic specimens.
(C) Kaplan Meier survival curves showing significantly shorter survival in primary tumors expressing higher PKCε.
(D) Alignment of amino acid sequences flanking Thr52 in ATF2, as compared to consensus sequence used as PKCε inhibitor peptide.
(E) Schematic representation of PKCε-mediated regulation of the subcellular localization and, therefore, the oncogene or tumor suppressor activities of ATF2.
See also Figure S7.and 6D). Correspondingly, LU1205 and 501Mel cells were more
resistant to cell death compared with UACC903, SCC9, or P9
(an SCC line with low PKCε levels) (Figure S6A), further sup-
porting the notion that melanoma resistance to genotoxic
stress-induced cell death is due to impaired mitochondrial
translocation of ATF2. Consistent with these observations and
the nuclear localization of the ATF2T52E mutant, immunostain-
ing with the pT52 antibody detected only nuclear ATF2
(Figure S7A). These findings suggest that elevated PKCε levels
in melanoma cells inhibit ATF2 localization and function at the
mitochondria, thereby attenuating its role in promoting cell
death following genotoxic stress.
To establish the relationship between PKCε activity, pT52
phosphorylation, and sensitization to genotoxic stress-inducedapoptosis, we manipulated PKCε or ATF2 in MEL501 and
SCC9 cells. Whereas MEL501 cells exhibit high levels of PKCε,
T52 phosphorylation, and impaired ATF2 translocation to the
mitochondria (Figure 6C, 6D and 7A), SCC9 have low levels
of PKCε, T52 phosphorylation, and ATF2 localization at the
mitochondria following genotoxic stress (Figures 1, 6C, and
7A). ETO or UVC treatment, combined with PKCε-i or expression
of PKCε-targeted siRNA, sensitized 501MEL to genotoxic
stress-induced cell death (Figures 6E and S5C). Conversely,
ATF2T52E-expressing SCC9 cells exhibited lower levels of the
early apoptotic marker Annexin-V in response to ETO, PKCε-i,
or a combination of both, compared to EV- or ATF2WT-express-
ing cells (Figure S6B), corroborating the prosurvival function
associated with T52 phosphorylation. Intriguingly, althoughCell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 551
stable EV, ATF2WT, or ATF2T52E expression in SCC9 cells
produced no significant effects in proliferation rate during non-
stressed conditions, ATF2T52E conferred a survival advantage
when the cells were grown in the presence of ETO (Figure S6C),
further demonstrating the prosurvival effects conferred by
pT52-ATF2.
High Expression of PKCε in Melanoma Tumors
Is Associated with Poor Prognosis
To assess the nature of the differences in genotoxic stress
resistance between melanoma and SCC cells, we surveyed the
degree of PKCε expression and activity in a panel of melanoma
cell lines and a large cohort of melanoma tissue arrays (TMA).
Overall, melanoma cell lines exhibited higher PKCε expression
than primary keratinocytes, melanocytes, or SCC lines (Fig-
ure 7A). Of note, pT52 was lowest in primary keratinocytes and
melanocytes, whereas its levels were highest in 501Mel and
LU1205, where total and pS729 (active) PKCε levels are the
highest.
We next studied the association between PKCε expression
levels, patient survival, and other clinical and pathological
factors. IHC of a melanoma TMA revealed fairly homogenous
cytoplasmic/membranous staining within each histospot (Fig-
ure S7B). Immunofluorescent intensity was measurable in 427
histospots (171 primary and 256 metastatic cases).
PKCε expression was higher in metastatic than primary spec-
imens (p < 0.0001), as shown in Figure 7B. In primary speci-
mens, PKCε levels were higher in thicker lesions (p < 0.0001)
and in ulcerated lesions (p = 0.0004). PKCε expression did not
correlate with age, gender, or presence of tumor-infiltrating
lymphocytes.
Cox univariate survival analysis of continuous immunofluo-
rescent intensity scores indicated that high PKCε expression
was associated with decreased survival in the primary cohort
(p = 0.00042), but not in the metastatic subset (p = 0.887).
Multivariate analysis of PKCε expression did not retain its
independent prognostic value, presumably due to the strong
association with Breslow depth. To visually demonstrate the
association between PKCε expression and survival, we dichot-
omized the continuous scores by the median score. High
PKCε expression was not associated with survival in the
metastatic subset of patients (log rank p = 0.8; Figure S7C)
but, rather, was strongly associated with decreased survival
in the primary cohort (log rank p = 0.0004; Figure 7C), consis-
tent with our earlier analyses of a similar cohort in which
nuclear localization of ATF2 correlated with poor prognosis
(Berger et al., 2003).
Recent global mRNA expression profiling analyses (Yu et al.,
2008) revealed that ATF2 and VDAC1 expression are highly
correlated in nonmalignant tissue samples but significantly less
correlated in basal cell carcinoma (Figures S7D and S7E).
Independent expression profiling of metastatic versus nonmeta-
static melanoma (Xu et al., 2008) also identified that ATF2 and
VDAC1 expression are significantly more correlated in primary
melanoma than in aggressive metastases (Figures S7F and
S7G). These analyses are consistent with the ability to predict
cancer outcome using dynamic modularity in protein interaction
networks (Taylor et al., 2009).552 Cell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc.DISCUSSION
A number of transcription factors, including Myc, Notch,
and b-catenin, exhibit both oncogenic and tumor suppressor
activities (Koch and Radtke, 2007; Larsson and Henriksson,
2010), yet the mechanism(s) controlling their opposing functions
are largely associated with a given tissue/cell type. Here, we
demonstrate that the tumor suppressor or oncogenic activities
of ATF2 result from its cytosolic or nuclear function, respectively
(Figure 7E). Cytosolic localization of ATF2 has been seen
in nonmalignant skin tumors where ATF2 exhibits tumor
suppressor activity. Thus, mice expressing a transcriptionally
inactive form of ATF2 in keratinocytes developed more rapid
and larger skin papillomas than wild-type mice when subjected
to DMBA-TPA skin carcinogenesis (Bhoumik et al., 2008). In
addition, p53 mutant mice lacking ATF2 in mammary tissues
had a higher incidence of mammary tumors (Maekawa et al.,
2008). In contrast to these tumor suppressor activities, ATF2
plays an oncogenic role in malignant melanoma. Inactivation
of ATF2 in melanocytes attenuates melanoma formation in
the mutant N-Ras/Ink4a model (Shah et al., 2010). Unlike in
BCC/SCC, where ATF2 is also cytosolic, ATF2 is predominantly
nuclear in melanoma, which is associated with poor prognosis
(Berger et al., 2003).
The present findings reveal that, following genotoxic stress,
cytosolic ATF2 impairs HK1/VDAC1 complexes and mitochon-
drial membrane integrity, sensitizing cells to apoptosis. In
contrast, the high PKCε expression in melanoma cells induces
predominantly nuclear localization of ATF2, which attenuates
its normal cytosolic function and correlates with resistance to
genotoxic stress. Of note, the different levels of PKCε activity
found inmelanomas determine the extent towhich ATF2 reaches
the mitochondria and promotes cell death following genotoxic
stress. Thus, PKCε dictates the tumor suppressor or oncogenic
activities of ATF2 by directly affecting its nuclear or cytosolic
localization.
Though transcription factors such as p53, CREB, Stat3, and
Elk-1 have been reported to localize at the mitochondria (Barrett
et al., 2006; Lee et al., 2005; Mihara et al., 2003; Wegrzyn et al.,
2009), the finding that ATF2 can switch between its oncogenic
transcriptional function and its tumor suppressor mitochondrial
function presents a new paradigm for transcription factor regu-
lation and function. We show that the ability of ATF2 to abrogate
the HK1/VDAC complex is perturbed in melanomas, which
offers insight into the mechanisms underlying the notorious
resistance of melanoma to therapy. Consistent with this, HK/
VDAC1 complexes are increased in cancer cells and are associ-
ated with induction of the Warburg effect and a tumorigenic
advantage (Mathupala et al., 2006). PKCε may play an indirect
role in the metabolic changes that contribute to cancer develop-
ment and/or progression, as suggested by the observation that
elevated PKCε activity antagonizes the HK1/VDAC1-perturbing
function of ATF2. Of note, Bax activation is induced by ATF2T52A
and reduced by ATF2T52E (Figure S5E), which may be associ-
ated with the effect seen on HK1/VDAC or may be reflective of
additional activities elicited by cytosolic/mitochondrial ATF2.
Multivariate analysis did not identify PKCε expression as an
independent prognostic marker for melanoma, implying that it
may not be a driver of melanoma progression. This would be
consistent with our finding that ATF2T52E confers a survival
advantage during genotoxic stress but does not confer a pro-
liferative advantage (Figures S6B and S6C) or anchorage-
independent growth (data not shown). The upregulation of
PKCε seen in metastatic melanomas explains how ATF2 mito-
chondrial function is attenuated and why nuclear localization of
ATF2 is associated with poor prognosis in melanoma. Although
many cancers show a correlation between elevated PKCε
expression/activity and poor prognosis and chemotherapeutic
resistance, the ATF2 status in these tumors is unknown (Bae
et al., 2007). Of note, efforts to target PKCε for cancer therapy
have met with limited success, primarily because of its similarity
to PKCd (Gonelli et al., 2009). Small molecules that induce
cytosolic localization of ATF2 may thus represent a new class
of compounds with a unique advantage for therapy, and more
specific PKCε inhibitors may also be effective in this capacity.
We previously identified 10 and 50 aa ATF2-derived peptides
that inhibited the transcriptional activity and increased the
cytosolic localization of ATF2 (Bhoumik et al., 2004). These
peptides (which encompassed T52) sensitized melanoma cells
to apoptosis and inhibited melanoma growth in syngeneic
mice and in human melanoma xenografts (Bhoumik et al.,
2002). Based on our current findings, we propose that these
peptides competitively inhibited PKCε phosphorylation of
endogenous ATF2, thereby enabling its cytosolic localization
and mitochondrial function. Consistent with this, mutation of
T52 within the peptides abolished their inhibitory effects (Bhou-
mik et al., 2004). Strikingly, the amino acid sequences flanking
T52 showedmarked similarities to known PKC peptide inhibitors
and satisfied the requirements for optimal PKC substrate
sequence (Nishikawa et al., 1997). Though most PKC isoen-
zymes strongly prefer peptides with basic amino acids at
the 2 position, PKCε also accepts glutamic acid, which is the
residue found at this position in the ATF2 peptide (Figure 7D).
Our findings suggest a need to re-evaluate the functional
significance of T52 phosphorylation by PKCε to ATF2 tran-
scriptional activity and the relationship to phosphorylation
on Thr69/71 by JNK/p38. We showed that caPKCε induces
25-fold increase in Jun2-promoter activity, compared to
only 6-fold increased activity induced by ATF2T52E (Figures
3G and 3H), suggesting that PKCε may augment ATF2 phos-
phorylation by JNK, p38, or other PKC isoforms (Yamasaki
et al., 2009). T52 phosphorylation of ATF2 may also affect the
transcriptional function of ATF2 or its heterodimerization
partners (Liu et al., 2006) and/or the role of ATF2 in the DNA
damage response, which requires its phosphorylation on
S490/498 by ATM (Bhoumik et al., 2005).
Collectively, our results establish the role of ATF2 at the
mitochondria following genotoxic stress and reveal its con-
tribution to stress-induced cell death. The degree of PKCε
phosphorylation of ATF2 is instrumental in controlling its
function. PKCε phosphorylation determines the ability of ATF2
to function at the mitochondria, where its contribution to cell
death is consistent with its tumor suppressor functions.
Constitutively high PKCε expression/activity, as seen in mela-
nomas, attenuates ATF2 mitochondrial function and enhances
its nuclear transcriptional activity, consistent with its oncogenicactivity. Thus, PKCε regulates the subcellular localization of




Squamous cell carcinoma (SCC9) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM):F-12 (50:50) (Hyclone/Thermo Scientific,
USA) supplemented with 400 ng/ml hydrocortisone, 10% fetal bovine
serum (FBS), and antibiotics. Melanoma cell lines, M7, P9, and human skin
fibroblasts were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS and antibiotics. Normal human epidermal
keratinocytes (NHEK) cells were maintained in KGM-2 growth medium (Lonza,
USA). Melanocytes were maintained in 254 Medium (Invitrogen, CA, USA).
Antibodies and Immunostaining Reagents
Antibodies employed were purchased as follows: ATF2 (20F1), HK1 (C35C4),
HK2 (C64G5), HA (C29F4, for immunoblot analysis), and COXIV (3E11) from
Cell Signaling Technologies (MA, USA); b-actin (9), HIS-probe (H-15), HSP90
(4F10), Lamin A (N-16), PKCε (C15), TOM20 (F-10), and VDAC1 (20B12) from
Santa Cruz Biotechnology, Inc. (CA, USA); HA (3F10, for immunofluorescent
staining) from Roche; COXI (21C11BC11), COXII (2E3), COX IV (20E8), and
pS729 PKCε (44977G) from Invitrogen (CA, USA); HSP60 (24) from BD
PharMingen (USA); pT52 ATF2 from PhosphoSolutions (CO, USA); and Bax
(6A7) from ExAlpha Biologicals (MA, USA). MitoTracker Red CMXRos, PKCε
translocation inhibitor, Go¨6850, and Leptomycin B were purchased from
Invitrogen (CA, USA), Santa Cruz Biotechnologies, (CA, USA), EMDChemicals
(NJ, USA), and Sigma (USA), respectively.
Immunocytochemical Analysis
After indicated treatments, coverslip-grown cells were fixed in fixation buffer
for 20 min at room temperature. Coverslips were then rinsed twice in phos-
phate buffer solution and permeabilized in permeabilization buffer for
20 min. Primary antibodies were applied at 1:250 dilution in staining buffer
overnight at 4C in a humid chamber. Coverslips were subsequently subject
to five standing 5 min washes in wash buffer. Secondary antibodies (Alexa
Fluor secondary 350, 488, or 568; Invitrogen) were applied at 1:250 dilution
in staining buffer for 2–3 hr at room temperature in a humid chamber in the
dark. Prior to mounting with Vectorshield with DAPI (Vector Laboratories,
CA), coverslips were washed twice more in wash buffer. Immunofluorescent
analysis was conducted on an Olympus TH4-100 fluorescent microscope.
R 3 Z planes per field were captured and analyzed using Slidebook V.4.1,
and Z projection images of average intensity were constructed using ImageJ
V.1.43u.
Analysis of ATF2 Transcriptional Activity
SCC9 cells were stably knocked down for ATF2 employing shRNA targeted
for ATF2 30UTR (ID: TRCN0000013713, Sigma, USA). In brief, lentiviral parti-
cles packaged with ATF2 30UTR shRNA or pLKO empty vector constructs
were generated and spin infected in the presence of 10 mg/ml polybrene
(Sigma, USA) onto SCC9 cells. After 14 hr of infection, media was changed
and cells were grown for an additional 8 hr before a second spin infection.
Media was changed subsequently, and cells were grown for an additional
3 days in the presence of 0.8 mg/ml puromycin (Sigma, USA). Knocked
down cells were plated in 96-well plates (3,000 cells/well). Each well was
transfected with 6 ng pCMV b-galactosidase, 12 ng pGL-Jun2-promoter
construct, and 30 ng of empty vector or pEF-HA-ATF2 (WT, T52A, or T52E
mutants) overnight using JetPrime (Polyplus, France). Luciferase activity was
evaluated using the Luciferase Assay System (Promega, WI) and was normal-
ized by standardized b-gal assay.
Measurement of Mitochondrial Membrane Potential and Mass
After treatment as indicated in the figure legend, cells were pulse labeled with
either 250 nM tetramethylrhodamine ethyl ester (TMRE; Invitrogen, CA, USA)
or 10 nM nonyl acridine orange (NaO; Invitrogen, CA) (in PBS) for 20 min atCell 148, 543–555, February 3, 2012 ª2012 Elsevier Inc. 553
37C to measure either membrane potential or mass, respectively. TMRE is
a cationic dye preferentially taken up by mitochondria and generally reflects
changes in overall mitochondrial membrane potential. NaO is a cardiolipin-
specific (mitochondrial-specific lipid) staining dye that is reflective of mito-
chondrial mass, which is generally unchanged during acute membrane
potential changes (King et al., 2007). After labeling, cells were harvested by
trypsinization and resuspended in 150 nM TMRE or 5 nM NaO, respectively,
and analyzed immediately by fluorescence-activated cell sorting (FACS).
n = 10,000 cells (within whole-cell gates) per replica in over three independent
experiments. FACS data were subsequently analyzed by FlowJo software
(TreeStar, OR, USA).
Immunoprecipitation of VDAC1:HK1:ATF2 Complexes
After indicated treatments, cells were washed once with PBS at room
temperature and crosslinked with 1 mM dimethyl 3,30-dithiopropionimidate
dihydrochloride (DTBP; Sigma, USA) in PBS. Cells were harvested and pel-
leted, washed five times with PBS, and resuspended in lysis buffer for
20 min on ice (1% Triton X-100/0.05% CHAPS/20 mM Tris [pH 7.5]/
150 mM NaCl/1 mM EDTA/1 mM EGTA/protease and phosphatase inhibi-
tors). Cell lysates were sonicated with a microtip sonicator (Fisher Scientific
Sonic Dismembrator, Model 100) for 5 s (setting 1:4 W output) on ice and
pelleted, and resulting supernatant was reserved. Pellets were resuspended
in new lysis buffer and sonicated again for 15 s (setting 2:6 W output) on
ice. Twice-sonicated lysates were pelleted, and supernatants were combined
and subjected to immunoprecipitation overnight with indicated antibodies.
DNA Construct sh/siRNAs and Transfection Methods
DNA plasmids were all transfected using JetPrime according to manufac-
turer’s protocol (Polyplus, France). Lentiviral vector against PKCz and consti-
tutively active HIS-tagged PKCε were generous gifts from Dr. Jorge Moscat.
siRNA was transfected using RNAiMax according to manufacturer’s protocol
(Invitrogen, CA). All siRNAs were obtained from Ambion (USA): siHK1-1 (ID:
1599); siHK1-2 (1689); siHK2-1 (ID: 1433); siPKCε (ID: 677); and siPKCd
(ID: 775).
Tumor Microarray Analysis
Melanoma tissue microarrays have been previously described and were pro-
cessed as in Qi et al. (2010) with minor modifications for immunofluorescent
staining. PKCε antibody was applied at 1:300 dilution, and Alexa Fluor 488
secondary (Invitrogen) was applied at 1:400 dilution. The TMA was counter-
stained with 40,6-diamidino-2-phenylindole (DAPI). Images were captured by
fluorescencemicroscopic scanning, employing Aperio ScanScope. Integrated
signal intensity from all individual histospots was measured by two indepen-
dent scorers in blind manner, using ImageJ software. With the assistance of
a secondary blinded scorer, tumor spots were classified as uninterpretable if
they had insufficient tumor cells, loss of tissue, or abundant necrosis based
on DAPI counter staining. PKCε intensity scores ranged from 87 to 10,838
(median: 2764), and data were analyzed by a third evaluator.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.cell.2012.01.016.
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